Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.91 and traded as high as $3.27. XBiotech shares last traded at $3.21, with a volume of 60,445 shares traded.
XBiotech Price Performance
The stock's 50 day moving average is $2.95 and its two-hundred day moving average is $3.02. The stock has a market capitalization of $97.57 million, a PE ratio of -3.48 and a beta of 0.97.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter.
Hedge Funds Weigh In On XBiotech
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its holdings in XBiotech by 15.2% in the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock valued at $835,000 after purchasing an additional 27,909 shares in the last quarter. RBF Capital LLC acquired a new position in XBiotech in the second quarter valued at approximately $594,000. Charles Schwab Investment Management Inc. boosted its holdings in XBiotech by 15.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after purchasing an additional 8,918 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in XBiotech in the second quarter valued at approximately $142,000. Finally, Qube Research & Technologies Ltd acquired a new position in XBiotech in the second quarter valued at approximately $96,000. 55.70% of the stock is owned by institutional investors and hedge funds.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
See Also
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
